{"name":"Lipocine","slug":"lipocine","ticker":"LPCN","exchange":"NASDAQ","domain":"lipocine.com","description":"Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addit","hq":"Salt Lake City, UT","founded":0,"employees":"14","ceo":"Dr. Mahesh Patel","sector":"Endocrinology / Metabolic","stockPrice":2.37,"stockChange":0.05,"stockChangePercent":2.16,"marketCap":"$20M","metrics":{"revenue":1976677,"revenueGrowth":-67.2,"grossMargin":100,"rdSpend":8583919,"netIncome":-9627505,"cash":14930387,"dividendYield":0,"peRatio":-1.9,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"TLANDO patent cliff ($100.0M at risk)","drug":"TLANDO","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"LPCN 1154A","genericName":"LPCN 1154A","slug":"lpcn-1154a","indication":"Testosterone replacement therapy in hypogonadal men","status":"phase_3"},{"name":"Topical testosterone gel 1.62 %","genericName":"Topical testosterone gel 1.62 %","slug":"topical-testosterone-gel-1-62","indication":"Treatment of hypogonadism in adult males","status":"phase_3"},{"name":"LPCN 1021","genericName":"LPCN 1021","slug":"lpcn-1021","indication":"Testosterone replacement therapy in hypogonadal men","status":"phase_3"},{"name":"LPCN 1144 Formulation B","genericName":"LPCN 1144 Formulation B","slug":"lpcn-1144-formulation-b","indication":"Treatment of hypogonadism in men","status":"phase_2"},{"name":"Oral testosterone undecanoate, LPCN 1021","genericName":"Oral testosterone undecanoate, LPCN 1021","slug":"oral-testosterone-undecanoate-lpcn-1021","indication":"Testosterone replacement therapy in adult males with hypogonadism","status":"phase_3"}]}],"pipeline":[{"name":"LPCN 1154A","genericName":"LPCN 1154A","slug":"lpcn-1154a","phase":"phase_3","mechanism":"LPCN 1154A is a novel oral androgen receptor modulator that selectively activates androgen signaling in target tissues.","indications":["Testosterone replacement therapy in hypogonadal men"],"catalyst":""},{"name":"Topical testosterone gel 1.62 %","genericName":"Topical testosterone gel 1.62 %","slug":"topical-testosterone-gel-1-62","phase":"phase_3","mechanism":"Topical testosterone gel 1.62% works by delivering testosterone through the skin to increase androgen levels in the body.","indications":["Treatment of hypogonadism in adult males"],"catalyst":""},{"name":"LPCN 1021","genericName":"LPCN 1021","slug":"lpcn-1021","phase":"phase_3","mechanism":"LPCN 1021 is a novel oral androgen receptor agonist designed to deliver testosterone systemically for hormone replacement therapy.","indications":["Testosterone replacement therapy in hypogonadal men"],"catalyst":""},{"name":"LPCN 1144 Formulation B","genericName":"LPCN 1144 Formulation B","slug":"lpcn-1144-formulation-b","phase":"phase_2","mechanism":"LPCN 1144 Formulation B is a testosterone replacement therapy.","indications":["Treatment of hypogonadism in men"],"catalyst":""},{"name":"Oral testosterone undecanoate, LPCN 1021","genericName":"Oral testosterone undecanoate, LPCN 1021","slug":"oral-testosterone-undecanoate-lpcn-1021","phase":"phase_3","mechanism":"Oral testosterone undecanoate replaces deficient testosterone by providing exogenous androgen that binds to androgen receptors throughout the body.","indications":["Testosterone replacement therapy in adult males with hypogonadism"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Lipocine Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Lipocine reported net loss of $13.4 million for the fourth quarter and $54.4 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Lipocine Announces Collaboration with University of California, San Francisco","summary":"Lipocine partnered with the University of California, San Francisco to develop new treatments for metabolic disorders.","drugName":"","sentiment":"positive"},{"date":"2023-08-14","type":"regulatory","headline":"Lipocine Receives Complete Response Letter from FDA for TLANDO","summary":"The FDA issued a Complete Response Letter for Lipocine's New Drug Application for TLANDO, requesting additional information.","drugName":"","sentiment":"negative"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQLW1LaFpodHRQMUZMQVo0M29Yb2dvYjN3WFFyaUk3SXdBNnBKQnNUTHYtTW9aTlNMdkJ6RW1GOW5ZelR3REx6T1ZORzB5UmVXRG5UQWFxVDJHT1J1OS1DMF9ENm43d2hEM05JalpFcXhnX2tYdXgzM2JuTXE1UUNrM2R6d01SU2hRYVpGS2hsWFpWVUxGMVhQTVlHNU9ZQnBwUVo0b0ZDaFhEMk0?oc=5","date":"2026-04-02","type":"pipeline","source":"Benzinga","summary":"Nasdaq Down 1%; US Initial Jobless Claims Fall - Benzinga","headline":"Nasdaq Down 1%; US Initial Jobless Claims Fall","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9tSFNwU3ZhR2t5amI2TDFkQVhjZjh1ZU9WdnNXM0JzSHJqWXFBaUpRSVItVzhGQ0pWRmhwWnVIMmUxNURkVUV6aXp4NWhxcXpjNDZkVnNxTElWVXVmQ1HSAWNBVV95cUxNRVBFYm84RFc2dWxvanFLRHJadldFOHdwNDY3Skw2S1ZXdlplSlZlV3VNaTUtaWl0c3JXVEZKRkRjUGgyTkw5NlgyMk9CTTl6cGJWNndJaTlFV2tBM0FIY01xSFU?oc=5","date":"2026-04-01","type":"pipeline","source":"Bitget","summary":"Lipocine Tumbles 78.6% Intraday: Is This A Volatility Shock or a Reckoning? - Bitget","headline":"Lipocine Tumbles 78.6% Intraday: Is This A Volatility Shock or a Reckoning?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5xd01tSEI1VU9YUDl4V3ctVzBDYkZ2SURkOGl0S2Y3eG9BYTVTRXJjelhhenlyNzNneFA0a1JtWXBZMkVqNWFzSlA1bFIxY0JRNkkwUzhLc3RfaXFnb1huX3BEWFg0aFl3cHNCaUJB?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Lipocine Inc (LPCN) - Stock Titan","headline":"If You Invested $1,000 in Lipocine Inc (LPCN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPTlZ6VGIxQXUwWFpkbld5VUhfVGhqS1hWZ0pvMWRNeDVTYnE5RkMycTZpMUdGSVZ2Y2IyMEpfV1oySHFXQ0RBZkdmN21uaFJsVWxlTzl5X0NreW1DOHY2emxnX0xBOVNPVUN0S091RHp6cTN3MWVIWmJRQ0doYUE4RzJJMkd6RVFGWU4tSWIxU0QtSkFKY1paeGU1bmlqeG4tTHVKUFdJc0gyWWlG?oc=5","date":"2026-03-10","type":"pipeline","source":"Finviz","summary":"Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - Finviz","headline":"Lipocine Announces Financial Results for the Full Year Ended December 31, 2025","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1vNlJ4MWlxMlktOTBGby1TYUVtdHRDT2g5UGtuZXR4TlJFLVlIczdtUzJJM1d3N2ExLVI1WE5JeWNfZXFaM2RfTVBSclo5RGZ5VE4yTmNsWnVlTkdmdlVrUjJyUjY5SjVUOFRKeWhLVzN0OWV2c00ycQ?oc=5","date":"2026-02-27","type":"pipeline","source":"Yahoo Finance","summary":"Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance","headline":"Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"TLANDO","drugSlug":"testosterone-undecanoate","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000}],"drugCount":5,"phaseCounts":{"phase_3":4,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Endo International","Teva Pharmaceutical Industries","Pfizer Inc."],"therapeuticFocus":["Hypogonadism","Metabolic Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":1976677,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":1976677,"period":"2025-12-31"},{"value":11198144,"period":"2024-12-31"},{"value":11198144,"period":"2024-12-31"},{"value":-2850818,"period":"2023-12-31"},{"value":-2850818,"period":"2023-12-31"}],"grossProfit":-6607242,"grossProfitHistory":[{"period":"2025-12-31","value":-6607242},{"period":"2024-12-31","value":3846391},{"period":"2023-12-31","value":-13026069},{"period":"2022-12-31","value":-8056888}],"rdSpend":8583919,"rdSpendHistory":[],"sgaSpend":3764137,"operatingIncome":-10371379,"operatingIncomeHistory":[{"period":"2025-12-31","value":-10371379},{"period":"2024-12-31","value":-1155035},{"period":"2023-12-31","value":-17930957},{"period":"2022-12-31","value":-12119375}],"netIncome":-9627505,"netIncomeHistory":[{"period":"2025-12-31","value":-9627505},{"period":"2024-12-31","value":8352},{"period":"2023-12-31","value":-16352082},{"period":"2022-12-31","value":-10758636}],"eps":-1.77,"epsHistory":[{"period":"2025-12-31","value":-1.77},{"period":"2024-12-31","value":0},{"period":"2023-12-31","value":-3.14},{"period":"2022-12-31","value":-2.21}],"cash":5205842,"cashHistory":[{"period":"2025-12-31","value":5205842},{"period":"2024-12-31","value":6205926},{"period":"2023-12-31","value":4771758},{"period":"2022-12-31","value":3148496}],"totalAssets":17005612,"totalLiabilities":2528196,"totalDebt":2310825,"equity":14477416,"operatingCashflow":-9760721,"operatingCashflowHistory":[{"period":"2025-12-31","value":-9760721},{"period":"2024-12-31","value":-1221233},{"period":"2023-12-31","value":-11865991},{"period":"2022-12-31","value":-11968819}],"capex":-90086,"capexHistory":[{"period":"2024-12-31","value":-90086},{"period":"2023-12-31","value":-13167},{"period":"2022-12-31","value":-133831},{"period":"2021-12-31","value":-7591}],"freeCashflow":-9760721,"dividendsPaid":null,"buybacks":-21700,"employees":14,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":983390,"ebit":-2515801,"ebitda":-2500820,"period":"2025-12-31","revenue":1145390,"epsBasic":null,"netIncome":-2370084,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":-2515801},{"sga":767837,"ebit":-3361040,"ebitda":-3346917,"period":"2025-09-30","revenue":114574,"epsBasic":-0.59,"netIncome":-3186832,"rdExpense":2707777,"epsDiluted":-0.59,"grossProfit":null,"operatingIncome":-3361040},{"sga":890433,"ebit":-2404353,"ebitda":-2388245,"period":"2025-06-30","revenue":622849,"epsBasic":-0.41,"netIncome":-2205716,"rdExpense":null,"epsDiluted":-0.41,"grossProfit":-1513920,"operatingIncome":-2404353},{"sga":1122477,"ebit":-2090184,"ebitda":-2074614,"period":"2025-03-31","revenue":93864,"epsBasic":-0.35,"netIncome":-1864873,"rdExpense":1061571,"epsDiluted":-0.35,"grossProfit":null,"operatingIncome":-2090184},{"sga":873055,"ebit":1545479,"ebitda":1561050,"period":"2024-12-31","revenue":3491406,"epsBasic":null,"netIncome":1782183,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":1545479},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.41,"netIncome":null,"rdExpense":1585233,"epsDiluted":-0.44,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2.37,"previousClose":2.32,"fiftyTwoWeekHigh":12.37,"fiftyTwoWeekLow":1.81,"fiftyTwoWeekRange":"1.81 - 12.37","fiftyDayAverage":4.61,"twoHundredDayAverage":4.78,"beta":0.5,"enterpriseValue":2965456,"forwardPE":-1.9,"priceToBook":1.01,"priceToSales":9.88,"enterpriseToRevenue":1.5,"enterpriseToEbitda":-0.29,"pegRatio":0,"ebitda":-10310597,"ebitdaMargin":0,"freeCashflow":-6871981,"operatingCashflow":-9760721,"totalDebt":449591,"debtToEquity":3.1,"currentRatio":6.68,"returnOnAssets":-32.8,"returnOnEquity":-54.3,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":1,"targetMeanPrice":6,"targetHighPrice":6,"targetLowPrice":6,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.6,"institutionHeldPercent":23.1,"sharesOutstanding":8244253,"floatShares":6478107,"sharesShort":154115,"shortRatio":0.18,"shortPercentOfFloat":1.9,"epsTrailing":-1.96,"epsForward":-1.24,"revenuePerShare":0.36,"bookValue":2.35,"officers":[{"age":68,"name":"Dr. Mahesh V. Patel Ph.D.","title":"Co-Founder, President, CEO & Director"},{"age":57,"name":"Ms. Krista  Fogarty","title":"Principal Accounting Officer & Corporate Controller"},{"age":56,"name":"Dr. Nachiappan  Chidambaram Ph.D.","title":"Senior Vice President of Research & Development"},{"age":55,"name":"Mr. Logan  Morse","title":"Vice President of Sales, Marketing & Operations"},{"age":67,"name":"Dr. Anthony  DelConte M. D., M.D.","title":"Chief Medical Director"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.lipocine.com","phone":"801 994 7383"}}